Filing Flows › Myriad Genetics (MYGN) › R&D spending
Myriad Genetics (MYGN) R&D spending by quarter
Myriad Genetics' R&D spending was $26.5M in Q3 2026 (third quarter 2026), +6% from Q2 2026. Over the last 7 quarters it ranged from $25.0M (Q2 2026) to $28.2M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $26.5M | +6% | -6% |
| Q2 2026 | $25.0M | -8% | -2% |
| Q1 2026 | $27.1M | +6% | -1% |
| Q4 2025 | $25.5M | -10% | — |
| Q3 2025 | $28.2M | +10% | — |
| Q2 2025 | $25.6M | -7% | — |
| Q1 2025 | $27.5M | — | — |
Q3 2026 at a glance
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Myriad Genetics' R&D spending?
Myriad Genetics' R&D spending was $26.5M in Q3 2026 (third quarter 2026), +6% from Q2 2026.
How has Myriad Genetics' R&D spending changed?
Over the last 7 quarters it ranged from $25.0M (Q2 2026) to $28.2M (Q3 2025).